You should seek medical advice in relation to medicines and use only as directed by a healthcare professional.
Always read the label. If symptoms persist see your healthcare professional.
Asthma: DuoResp Spiromax is indicated in adults (18 years and older) for the treatment of asthma, to achieve overall asthma control, including the relief of symptoms and the reduction of the risk of exacerbations (see Section 4.2 Dose and method of administration).,DuoResp Spiromax is not indicated in children and adolescents under the age of 18 years as the 100/6 dose is not available.,Chronic Obstructive Pulmonary Disease (COPD):
DuoResp Spiromax is indicated for the symptomatic treatment of moderate to severe COPD (FEV1=50% predicted normal) in adults with frequent symptoms despite long-acting bronchodilator use, and/or history of recurrent exacerbations. DuoResp Spiromax is not indicated for the initiation of bronchodilator therapy in COPD.
This medicine was verified as being available on the PBS (Pharmaceutical Benefits Scheme) on December, 1 2024. To learn more about this subsidy, visit the Pharmaceutical Benefits Scheme (PBS) website.
Reporting side effects
You can help ensure medicines are safe by reporting the side effects you experience.
Asthma: DuoResp Spiromax is indicated in adults (18 years and older) for the treatment of asthma, to achieve overall asthma control, including the relief of symptoms and the reduction of the risk of exacerbations (see Section 4.2 Dose and method of administration).,DuoResp Spiromax is not indicated in children and adolescents under the age of 18 years as the 100/6 dose is not available.,Chronic Obstructive Pulmonary Disease (COPD):
DuoResp Spiromax is indicated for the symptomatic treatment of moderate to severe COPD (FEV1=50% predicted normal) in adults with frequent symptoms despite long-acting bronchodilator use, and/or history of recurrent exacerbations. DuoResp Spiromax is not indicated for the initiation of bronchodilator therapy in COPD.
This medicine was verified as being available on the PBS (Pharmaceutical Benefits Scheme) on December, 1 2024. To learn more about this subsidy, visit the Pharmaceutical Benefits Scheme (PBS) website.
Reporting side effects
You can help ensure medicines are safe by reporting the side effects you experience.
Asthma: DuoResp Spiromax is indicated in adults (18 years and older) for the treatment of asthma, to achieve overall asthma control, including the relief of symptoms and the reduction of the risk of exacerbations (see Section 4.2 Dose and method of administration).,DuoResp Spiromax is not indicated in children and adolescents under the age of 18 years as the 100/6 dose is not available.,Chronic Obstructive Pulmonary Disease (COPD):
DuoResp Spiromax is indicated for the symptomatic treatment of moderate to severe COPD (FEV1=50% predicted normal) in adults with frequent symptoms despite long-acting bronchodilator use, and/or history of recurrent exacerbations. DuoResp Spiromax is not indicated for the initiation of bronchodilator therapy in COPD.
This medicine was verified as being available on the PBS (Pharmaceutical Benefits Scheme) on December, 1 2024. To learn more about this subsidy, visit the Pharmaceutical Benefits Scheme (PBS) website.
Reporting side effects
You can help ensure medicines are safe by reporting the side effects you experience.
Government Accredited with over 140 information partners
We are a government-funded service, providing quality, approved health information and advice
Healthdirect Australia acknowledges the Traditional Owners of Country throughout Australia and their continuing
connection to land, sea and community. We pay our respects to the Traditional Owners and to Elders both past and
present.
